Table 1 Characteristics of included individual studies
Author | Year | Country | Design | Treatment | Mean age (years) | Case (hip) | Inclusion criteria | Follow-up (years) | Outcomes |
|---|---|---|---|---|---|---|---|---|---|
Gangji [24] | 2011 | Belgium | RCT | CD BMAC | 45.7 42.2 | 11 13 | ARCO I-II | 5 | THA, Progress |
Sen [25] | 2012 | India | RCT | CD BMAC | 31.1 34.7 | 25 26 | ARCO I-II | 2 | Progress |
Zhao [26] | 2012 | China | RCT | CD MSCs | 33.8 32.7 | 44 53 | ARCO I-II | 5 | THA, Progress |
Rastogi [27] | 2013 | India | RCT | CD BMAC | 33 34.7 | 30 30 | ARCO I-III | 2 | THA, Progress |
Ma [28] | 2014 | China | RCT | ABG ABG + BMAC | 34.8 35.6 | 24 25 | Ficat I-III | 2 | THA, Progress |
Tabatabaee [29] | 2015 | Iran | RCT | CD BMAC | 29.1 29.1 | 14 14 | ARCO I-III | 2 | THA, Progress |
Pardos [30] | 2016 | Spain | Retrospective cohort | CD BMAC | 36.7 42.6 | 19 41 | Ficat I-II | 4 | THA, Progress |
Pepke [31] | 2016 | Germany | RCT | CD BMAC | 44.5 44.3 | 14 11 | ARCO II | 2 | THA, Progress |
Sallam [32] | 2017 | Egypt | Retrospective cohort | CD ABG | 33.2 32.6 | 38 33 | Ficat I-III | 3 | THA, Progress |
Hauzeur [33] | 2017 | Belgium | RCT | CD BMAC | 49.7 48 | 23 23 | ARCO III | 2 | THA, Progress |
Cao [34] | 2017 | China | RCT | CD FVBG | 31 31 | 21 21 | ARCO I-III | 3 | THA, Progress |
Feng [35] | 2019 | China | Retrospective cohort | FVBG ABG | 33.2 32.8 | 84 51 | ARCO III | 6 | THA, Progress |
Hauzeur [36] | 2019 | Belgium | RCT | BMAC MSCs | 50 51 | 26 27 | ARCO I-II | 3 | THA, Progress |
Aggarwal [37] | 2020 | India | RCT | CD PRP | 35.2 38.2 | 28 25 | ARCO I-II | 1 | THA, Progress |
Li [17] | 2020 | China | RCT | ABG ABG + BMAC | 38.2 34.1 | 24 25 | Ficat I-III | 2 | THA, Progress |
Hoogervorst [38] | 2022 | America | Retrospective cohort | CD BMAC | 39.8 33.1 | 24 61 | ARCO I-IV | 5 | THA, Progress |
Wan [39] | 2022 | China | RCT | ABG FVBG | 29.6 28.8 | 45 46 | ARCO II | 4 | THA, Progress |